Development and Characterization of Monoclonal Antibodies Against AMPylation, Upcoming Webinar Hosted by Xtalks

TORONTO, Feb. 16, 2021 /PRNewswire-PRWeb/ -- Post-translational modifications (PTMs) substantially broaden the range of function of a given set of proteins, and their identification, as well as understanding their regulation, is of significant research interest. However, due to the challenge of recognizing a small moiety with high affinity, as well as the necessity to recognize small but important differences between modifications and the associated danger of cross reactivity, developing antibodies against PTMs is a complex task. The process becomes even more challenging when the general recognition of a PTM independent of the protein sequence is required.

AMPylation, which has been described in the context of bacterial infection as well as protein homeostasis in the past, is a PTM where reliable antibodies could significantly expand the understanding of its role in signal transduction. This webinar will focus on the development of monoclonal anti-AMP antibodies in mice, as part of a collaborative effort with GenScript, that was recently published in iScience. The design of the synthetic AMPylated peptide for immunization, the selection process to ensure specific binding and backbone-independent recognition, as well as the characterization of lead antibodies and their potential for the future will be discussed.

GenScript antibody services are highly customizable and can be tailored to your specific research needs and we have generated greater than 17,000 mAbs and 130,000 pAbs. For more information please visit here.

Join Dorothea Höpfner, Doctoral Candidate in the Department of Chemistry, Technical University of Munich in a live webinar on Wednesday, March 3, 2021 at 9:30am EST (2:30pm GMT/UK) to hear about the development of monoclonal anti-AMP antibodies in detail.

For more information, or to register for this event, visit Development and Characterization of Monoclonal Antibodies Against AMPylation.

About GenScript

GenScript is the world leader in biotechnology reagent services and biologics. Established in 2002 in New Jersey, United States, the company was the first to commercialize gene synthesis and successfully establish fully integrated capabilities for custom peptide synthesis, protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology as well as a variety of catalogue products. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early stage pharmaceutical development. In addition to providing the best in class biological reagents such as antibodies, GenScript has now expanded its business into immunotherapy, CDMO, laboratory equipment, and microbial industry to further fulfill its mission in making people and nature healthier through biotechnology.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Sydney Perelmutter, Xtalks, +1 (416) 977-6555 x 352, [email protected]

SOURCE Xtalks

Related Links

https://xtalks.com/